- Home
- ARMP vs TURN Comparison
ARMP vs TURN Comparison
Compare ARMP & TURN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- TURN
- Stock Information
- Founded
- ARMP N/A
- TURN 1981
- Country
- ARMP United States
- TURN United States
- Employees
- ARMP N/A
- TURN N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- TURN Finance/Investors Services
- Sector
- ARMP Health Care
- TURN Finance
- Exchange
- ARMP Nasdaq
- TURN Nasdaq
- Market Cap
- ARMP 52.1M
- TURN 42.5M
- IPO Year
- ARMP N/A
- TURN N/A
- Fundamental
- Price
- ARMP $2.54
- TURN $4.27
- Analyst Decision
- ARMP Strong Buy
- TURN
- Analyst Count
- ARMP 1
- TURN 0
- Target Price
- ARMP $9.00
- TURN N/A
- AVG Volume (30 Days)
- ARMP 13.2K
- TURN 38.5K
- Earning Date
- ARMP 08-12-2025
- TURN 01-01-0001
- Dividend Yield
- ARMP N/A
- TURN N/A
- EPS Growth
- ARMP N/A
- TURN N/A
- EPS
- ARMP N/A
- TURN N/A
- Revenue
- ARMP $4,699,000.00
- TURN $194,813.00
- Revenue This Year
- ARMP $8.43
- TURN N/A
- Revenue Next Year
- ARMP N/A
- TURN N/A
- P/E Ratio
- ARMP N/A
- TURN N/A
- Revenue Growth
- ARMP 14.24
- TURN 254.25
- 52 Week Low
- ARMP $0.90
- TURN $3.12
- 52 Week High
- ARMP $2.96
- TURN $4.31
- Technical
- Relative Strength Index (RSI)
- ARMP 65.04
- TURN 71.35
- Support Level
- ARMP $2.14
- TURN $4.20
- Resistance Level
- ARMP $2.61
- TURN $4.31
- Average True Range (ATR)
- ARMP 0.14
- TURN 0.10
- MACD
- ARMP -0.00
- TURN 0.01
- Stochastic Oscillator
- ARMP 81.08
- TURN 87.90
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.